HOME >> MEDICINE >> NEWS
Low platelet counts linked to decreased survival in HIV-infected women

SAN DIEGO (Dec. 5, 2004) - HIV-positive women with low blood platelet counts face significantly higher risk of death compared to women with normal counts, according to a study presented today at the 46th Annual Meeting of the American Society of Hematology.

Findings come from the Women's Interagency HIV Study, or WIHS, a prospective study of women living with HIV (as well as HIV-negative women for comparison) in six urban areas across the United States. In this portion of the study, researchers looked at 1,990 HIV-infected women and 553 HIV-negative women.

When entering the study, 15 percent of HIV-positive women and less than 2 percent of the HIV-negative women had low blood platelet counts, also called thrombocytopenia. Platelets are minute cells in the blood that help in the blood clotting process.

The researchers found that women with thrombocytopenia-a platelet count of fewer than 50,000 platelets per cubic millimeter-had a five-fold increase risk of dying due to any cause, compared to women with normal platelet counts. Thrombocytopenia also was linked to a three-fold risk of dying due to AIDS.

"Only a low CD4+ lymphocyte count, one under 200 cells per cubic millimeter, could compare in the strength of its link to mortality," says WIHS principal investigator Alexandra M. Levine, M.D., Distinguished Professor of Medicine, chief of hematology at the Keck School of Medicine of USC and medical director of the USC/Norris Cancer Hospital. Physicians have long relied on counts of CD4+ lymphocyte as a key measure of immunosuppression in HIV-infected patients.

Fortunately, many women saw their platelet counts boosted back to normal through use of highly active antiretroviral therapy, or HAART, especially therapy containing zidovudine, also called AZT.

Researchers found that factors associated with increased risk of thrombocytopenia included HIV infection, low CD4+ lymphocyte counts, increasing viral load, and smoking. Int
'"/>

Contact: Sarah Huoh
shuoh@usc.edu
323-442-2830
University of Southern California
5-Dec-2004


Page: 1 2

Related medicine news :

1. Three anti-platelet drugs used in combination are safe
2. How platelets help cancer invade other tissues
3. Binge drinking: red wine and alcohol have different effects on platelets
4. Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective
5. Antiplatelet drugs: comparison of clopidogrel with aspirin
6. Study shows combining antiplatelet drug Abciximab with clot-buster is effective in treating heart-attack patients
7. Laser method identifies, counts toxic molecules
8. For healthy diet, learning level counts more than earning level
9. USC researchers find ozone lowers sperm counts
10. Hand size counts in safe handgun use
11. Study finds factors linked to substance use disorder relapse among health care professionals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick Taché ... Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is a ... & Medical Technology Group have been featured speakers at every DeviceTalks conference since 2011. ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that it had joined the ... as a non-profit organization to unite pharmaceutical and healthcare companies that share a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are ... this in mind, SIGVARIS has created a new line of anti-embolism stockings to ... and provide the benefits of graduated compression when transitioning from recovery to early ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
Cached News: